# An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Source: https://onco.cc/trials/nct07033026/  
OnCo record `nct07033026` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of NGM120 Q4W in colorectal cancer, run by NGM Biopharmaceuticals, Inc, now recruiting.

## Summary

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. is a phase 2 interventional study registered as NCT07033026 by NGM Biopharmaceuticals, Inc, with 136 participants planned, started 2025-06-25 and due to reach its primary completion in 2027-04. Interventions recorded: NGM120 Q4W, NGM120 Q8W and Placebo given.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07033026
- Phase: 2
- Setting: A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia
- Sponsor: NGM Biopharmaceuticals, Inc
- Enrolled: 136

## Sources

- ClinicalTrials.gov NCT07033026: https://clinicaltrials.gov/study/NCT07033026

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)

---
JSON: https://onco.cc/api/v1/entities/nct07033026.json